Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Shareholders held by Teva Pharmaceutical Industries Limited on June 5, 2025. The filing details the outcomes of votes regarding board composition, executive compensation, and auditor appointment.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and shareholder voting. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Voting Results
The following matters were submitted to and approved by shareholders:
- Board of Directors Elections:
- Chen Lichtenstein was elected to serve until the 2027 annual meeting.
- Amir Elstein, Roberto A. Mignone, Dr. Perry D. Nisen, and Dr. Tal Zaks were elected to serve until the 2028 annual meeting.
- All director nominees received majority support, though significant "Against" votes were recorded for each candidate.
- Executive Compensation: Shareholders approved, on a non-binding advisory basis, the compensation for named executive officers.
- Compensation Policies:
- Approved an amended Compensation Policy for Executive Officers and Directors.
- Approved an amendment to the terms of office and employment for the President and CEO.
- Approved amendments to compensation for non-employee Directors and the non-executive Chairman of the Board.
- Auditor Appointment: Shareholders approved the appointment of Kesselman & Kesselman (a member of PricewaterhouseCoopers International Ltd.) as the independent registered public accounting firm until the 2026 annual meeting.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. The document is strictly limited to the tabulation of shareholder votes.
Investor Verification Checklist
- Verify the tenure dates for the newly elected directors (2027 vs. 2028 terms).
- Review the specific details of the amended CEO employment terms and compensation policies referenced in the proxy statement.
- Confirm the transition of the independent auditor to Kesselman & Kesselman for the 2025-2026 period.
- Analyze the "Against" vote percentages for directors to assess shareholder sentiment regarding board composition.